Physician profile
Max Shrout
NPI 1184284507
$2,864.04
in general payments reported to CMS, 2019-2025
16 companies · $731 in 2025
The $731 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $949 · 2023: $636 · 2024: $433 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,702 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,701.86 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $484.53 | 2022-2023 | Tenoglide |
| Axogen | $314.79 | 2022-2025 | Avance Nerve Graft |
| Innovation Technologies INC | $278.71 | 2022-2024 | Irrisept |
| Polynovo North America LLC | $205.77 | 2025 | Novosorb Btm |
| Allergan, INC. | $190.50 | 2022 | |
| Davol INC. | $178.52 | 2025 | Channel Drain |
| Sientra, INC. | $161.60 | 2022 | |
| Mentor Worldwide LLC | $153.29 | 2021-2023 | Artoura Breast Tissue Expander, Mentor Memorygel Resterilizable Gel Sizer |
| Tela Bio, INC. | $146.34 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Musculoskeletal Transplant Foundation INC. | $146.04 | 2025 | |
| Revance Therapeutics, INC. | $140.21 | 2024 | Daxxify |
| Endo Pharmaceuticals INC. | $121.65 | 2022 | |
| Kls-Martin L.P. | $99.00 | 2025 | |
| Stryker Corporation | $98.79 | 2024 | Na |
| Zimmer Biomet Holdings, INC. | $95.23 | 2023 | Ncb |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $49.07 | 2024 | Restrata Wound Matrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Shrout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.